Table 2.
Pharmacokinetic parameters of PMX in rats after intravenous or oral administration of PMX or PMX/DL(1:1)-CD.
| Test material | PMX-IV (10) | PMX-Oral (20) | PMX/DL(1:1)-CD (10) | PMX/DL(1:1)-CD (20) | PMX/DL(1:1)-CD (40) |
|---|---|---|---|---|---|
| Administration route | IV | Oral | Oral | Oral | Oral |
| PMX dose (mg/kg) | 10 | 20 | 10 | 20 | 40 |
| Tmax (h) | – | 0.50 ± 0.00 | 0.50 ± 0.00 | 0.50 ± 0.00 | 0.50 ± 0.00 |
| T1/2 (h) | 0.954 ± 0.043 | 13.1 ± 1.82 | 15.3 ± 1.18 | 13.9 ± 1.25 | 8.11 ± 1.91 |
| Cmax (μg/mL) | 32.3 ± 1.22 | 0.579 ± 0.073 | 1.81 ± 0.225 | 3.85 ± 0.371 | 5.07 ± 0.624 |
| AUClast (μg·h/mL) | 25.1 ± 3.56 | 3.93 ± 0.380 | 7.02 ± 1.04 | 11.1 ± 1.71 | 12.7 ± 2.70 |
| AUCinf (μg·h/mL) | 25.3 ± 3.56 | 8.96 ± 0.089 | 19.7 ± 1.21 | 26.7 ± 4.65 | 20.7 ± 6.17 |
| Bioavailability (%) | 100 | 7.80 ± 0.755 | 27.9 ± 4.12 | 22.0 ± 3.40 | 12.6 ± 2.68 |
Tmax: time to reach the maximum plasma concentration of PMX; T1/2: plasma half-life of PMX; Cmax: maximum plasma PMX concentration; AUClast: area under the plasma concentration-time curve between zero and the last measurable plasma concentration; AUCinf: area under the plasma concentration-time curve between zero and infinity. Bioavailability (%) = (AUClast, oral/DosePMX, oral)/(AUClast, IV/DosePMX, IV) × 100. All values are means ± SDs (n = 4).